Developer docs
API playgroundTry for free, no card

Search company profiles

Applied DNA Sciences

Full company profile

uuid0000f2y

Namestring
Applied DNA Sciences
Legal namestring
Applied DNA Sciences, Inc.
Websiteurl
adnas.com
Company typeenum
Public
Founded yearint
1987
Descriptiontext

Applied DNA Sciences, now operating as BNB Plus Corporation (NASDAQ: BNBX, formerly APDN), is a Delaware-incorporated biotechnology company that has undergone a radical strategic transformation in 2025. Historically it sold botanical DNA-based anti-counterfeiting and supply chain authentication services (CertainT, SigNature DNA, fiberTyping) targeting textiles, pharmaceuticals and cannabis; today its commercial center of gravity is the LineaRx subsidiary, which produces enzymatically-synthesized linear DNA (LineaDNA) using proprietary large-scale PCR for mRNA production, gene therapy, cell therapy and veterinary vaccine applications. The Linea IVT platform combines LineaDNA IVT templates with a proprietary chemically-modified RNA polymerase (Linea RNAP, acquired from Spindle Biotech in July 2023) to address plasmid DNA bottlenecks and dsRNA contamination in mRNA manufacturing, and is supported by cGMP-certified production capacity in Stony Brook, NY, a Notice-of-Allowance on the Linea RNAP composition patent (protection into 2041), and a 70%+ manufacturing cost reduction achieved through the Alphazyme partnership.

The company generates revenue through B2B direct enterprise sales of LineaDNA products and custom manufacturing services to pharmaceutical companies, biotech firms, CDMOs and IVD manufacturers, supplemented by authentication services under multi-year contracts; pricing is quote-based and not publicly disclosed. Named enterprise customers include ÚHKT (CAR T Phase I trial), a Global IVD Manufacturer, Kudo Biotechnology, a Top-20 pharmaceutical manufacturer, an APAC-based mRNA CDMO and a US CRISPR/mRNA therapeutics developer, with veterinary research conducted alongside Cornell University. In June 2025 the company closed Applied DNA Clinical Labs and executed a 27% workforce reduction to focus resources on LineaRx; subsequently it rebranded as BNB Plus Corporation, changed its NASDAQ ticker to BNBX and committed up to $58M in private placement proceeds to a BNB cryptocurrency digital asset treasury strategy, pivoting its capital deployment away from pure biotech operations while retaining the LineaRx business as a continuing operating segment.

Short descriptiontext

Applied DNA Sciences (now BNB Plus Corporation, NASDAQ: BNBX) sells PCR-produced LineaDNA and the Linea IVT mRNA manufacturing platform to pharma, biotech, CDMO and IVD customers via its LineaRx subsidiary, while increasingly deploying capital into a BNB cryptocurrency treasury strategy following its 2025 strategic pivot.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersStony Brook, United States
HQ citystring
Stony Brook
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices3 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
enzymatic DNA production, mRNA therapeutics manufacturing, cell-free DNA synthesis, DNA authentication services, PCR-based biotherapeutics
Industry4 codes
SECONDARYHLAGAGAC
mRNA & Nucleic Acid Manufacturing Services (mRNA/saRNA/Plasmid DNA)
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Biopharma Manufacturing Services (Biologics/Cell & Gene)
SECONDARYHLAGABAF
mRNA/LNP & Nucleic Acid Therapeutics CDMO
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Contract Development & Manufacturing Organizations (CDMO)
SECONDARYHLAAACAN
Gene Therapy CMC/Process Development Platforms (capsid engineering, producer cell lines, plasmids, upstream/downstream)
Healthcare & Life Sciences/Biotechnology & Biologics/Gene Therapy (AAV/lentiviral/other vectors)
SECONDARYHLAAAKAD
Viral Vector Manufacturing Services (AAV, lentiviral, adenoviral)
NAICS code1 code
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
SIC code1 code
  • Services-Commercial Physical & Biological Research8731
Product category
Therapeutic DNA Manufacturing
Social media profiles3 records
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model3 records
1Therapeutic DNA Production (LineaRx)
TypeOthers
Description

Sale of LineaDNA products for use in mRNA production, gene therapy, cell therapy, and veterinary medicine applications. Revenue from IVT templates and related products for biotherapeutic manufacturing.

adnas.com
2Molecular Diagnostics Testing Services (Applied DNA Clinical Labs)
TypeOthers
Description

PCR-based DNA and RNA detection services for molecular diagnostics and genetic testing, including COVID-19 surveillance and pharmacogenomic testing

adnas.com
3Supply Chain Security and Authentication
TypeOthers
Description

DNA-based authentication services (CertainT, SigNature, fiberTyping) for industrial supply chain security including textiles, pharmaceuticals, and cannabis

adnas.com
Marketing channels6 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels3 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Technology or R&D, Operations, Personnel, Supply Chain, Marketing or Sales
Pricing details1 tier
1Enterprise/B2B pricing
ModelOtherBilling cadenceMulti-year contract
Notes

Quote-based / Not publicly disclosed. Products and services priced individually based on customer requirements and volume.

adnas.com
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Brand1 of 4 records shown
1LineaDNA
Description

Enzymatically-produced linear DNA platform for nucleic acid-based therapeutics including mRNA production, gene therapy, and cell therapy applications

adnas.com
+3 more records
Core offering1 text field

Applied DNA Sciences, through its LineaRx subsidiary, manufactures enzymatically-produced linear DNA (LineaDNA) via proprietary large-scale PCR for use in mRNA production, gene therapy, and cell therapy applications. The company also offers DNA-based supply chain authentication services (CertainT, SigNature DNA, fiberTyping) for textiles, pharmaceuticals, and cannabis, and operates a cGMP manufacturing facility for therapeutic DNA production.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 3 values shown
  • Over 70% reduction in Linea RNAP manufacturing costs
+2 more records
Product overview1 text field

Applied DNA Sciences operates primarily through its LineaRx subsidiary, offering a portfolio centered on enzymatic DNA production. The core offering is the LinearDNA platform—a cell-free PCR-based DNA manufacturing system that produces high-fidelity DNA constructs (100bp to 20kb) as an alternative to plasmid-based production. This platform feeds into the Linea IVT platform, which combines LinearDNA with proprietary Linea RNAP for mRNA and saRNA manufacturing. The company previously operated Applied DNA Clinical Labs (now ceased) for molecular diagnostics, and maintains CertainT/SigNature DNA authentication services for supply chain security. Recent strategic shift includes pivot to BNB cryptocurrency treasury management.

Product and service10 records
1LineaRx
CategorySubsidiary/Core Platform
Description

Majority-owned subsidiary focused on enzymatic production of LinearDNA for use in mRNA production, gene therapy, cell therapy, and advanced therapeutic modalities.

2LineaDNA (LinearDNA)
CategoryCore Product
Description

Enzymatically-produced linear DNA manufactured via proprietary large-scale PCR-based platform. Produces high-fidelity DNA constructs ranging from 100bp to 20kb in quantities from milligrams to grams, free of adventitious DNA sequences. Alternative to plasmid-based DNA manufacturing.

3Linea IVT Platform
CategoryPlatform
Description

Combines enzymatically-produced LineaDNA IVT templates with proprietary Linea RNA polymerase (RNAP) to enable mRNA and saRNA manufacturers to produce high-quality mRNA faster, eliminating plasmid DNA as starting material and reducing dsRNA contamination.

4Linea RNAP
CategoryCore Product Component
Description

Proprietary chemically-modified RNA polymerase enzyme acquired from Spindle Biotech. Core component of the Linea IVT platform enabling mRNA manufacturers to produce better mRNA faster with reduced dsRNA contamination. US patent protection expected into 2041.

5cGMP LinearDNA Production
CategoryManufacturing Service
Description

GMP-compliant manufacturing capabilities for therapeutic DNA production. Facility integrates rapid enzymatic PCR-based DNA production within cGMP framework ensuring thorough documentation and QC analysis, supporting transition from discovery to clinical and commercial applications.

6CertainT Authentication
CategoryAuthentication Service
Description

DNA-based authentication platform for supply chain security enabling verification of product authenticity through genetic polymorphism, molecular taggants, isotopic signatures, or other identifiers. Covers textile authentication, supply chain security, and anti-counterfeiting applications.

7SigNature DNA
CategoryAuthentication Service
Description

Proprietary DNA genotyping and mass-spectrometry based authentication service for identifying and verifying materials throughout supply chains. Uses molecular taggants for product authentication and supply chain integrity verification.

8fiberTyping
CategoryAuthentication Service
Description

DNA-based fiber authentication service for textile supply chain verification, enabling identification of fiber composition and origin to prevent counterfeiting and ensure quality control.

9LinearDNA-LNP Vaccine Platform
CategoryResearch Platform
Description

Lipid nanoparticle delivery system for LinearDNA constructs enabling intramuscular administration without electroporation. Enables therapeutic applications including cancer vaccines, protein replacement, and cell/gene therapies with simplified delivery compared to traditional approaches.

10TR8 PGx
CategoryDiagnostic Sub-Panel
Description

Pharmacogenomic sub-panel for indication-specific use, complementing full-panel testing. First sub-panel launched for Pre-emptive Oncology Care relating to fluoropyrimidine-based cancer therapeutics.

Scale indicator8 records

Each record includes

Type, Value, Description, Source

Partnership6 partners
1ÚHKT (Institute of Hematology and Blood Transfusion)
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2024-12-18
Description

ÚHKT utilizing Linea DNA as critical component in CD123-specific CAR T-cell therapy manufacturing. Linea DNA enables non-viral workflow to reduce manufacturing costs and timelines. Phase I clinical trial approved by Czech regulatory authority.

adnas.com
Strategic tierSecondaryTypeStrategic or Co-development PartnerAnnounced on2024-04-25
Description

Awarded contract for rapid vaccine development program

Strategic tierCoreTypeTechnology or IntegrationAnnounced on2024-03-18
Description

Manufacturing scale-up agreement for Linea RNAP. Alphazyme performed manufacturing process development to scale Linea RNAP from research to commercial scale. Project resulted in over 70% reduction in manufacturing costs and quantity sufficient for near-term demand.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2023-12-14
Description

Joint development agreement to integrate Linea IVT platform into Kudo Bio's commercial mRNA manufacturing workflows. Companies seeking to optimize mRNA quality, yields, and dsRNA mitigation at manufacturing scale. Plans for global co-marketing relationship.

Strategic tierSecondaryTypeStrategic or Co-development PartnerAnnounced on2023-09-14
Description

Sponsored research agreement for translational research to accelerate development of LineaDNA-LNP veterinary vaccine platform. Evaluating multiple LNP formulations and DNA sequence optimization for maximum immunogenicity.

Strategic tierCoreTypeTechnology or IntegrationAnnounced on2023-07-13
Description

Acquisition of Spindle Biotech for RNA manufacturing technology. Acquired Linea RNAP technology and expertise to expand mRNA production capabilities and address dsRNA contamination issues.

Recent move8 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

GenScript provides gene synthesis, plasmid manufacturing, and protein services to therapeutic developers, overlapping Applied DNA's enzymatic DNA production for mRNA and gene therapy customers. Both target pharma/biotech CDMO and academic customers with custom DNA and RNA products.

TypeBroad incumbent
Description

BioNTech is an mRNA therapeutics developer and manufacturer that both consumes IVT DNA inputs (overlapping with Applied DNA's customer base) and is developing proprietary manufacturing capabilities that could substitute for external CDMOs like LineaRx.

TypeEmerging player
Description

Codexis engineers enzymes and biocatalysts for nucleic acid and small molecule manufacturing, including DNA/RNA synthesis applications. Its enzyme engineering capability is adjacent to Applied DNA's Linea RNAP and PCR-based enzymatic DNA approach and could become a competitor or partner in enzyme-based nucleic acid manufacturing.

TypeDirect peer
Description

Aldevron is a CDMO producing plasmid DNA, mRNA, and proteins for cell and gene therapy developers. It competes head-on with Applied DNA's LineaRx offering as a supplier of DNA inputs to gene therapy and cell therapy manufacturers.

TypeDirect peer
Description

TriLink is a leading mRNA and nucleic acid CDMO that manufactures IVT templates, mRNA, and CleanCap capping analog — directly overlapping Applied DNA's LineaDNA IVT and Linea IVT platform offering for mRNA therapeutics developers. Both target the same CDMO and therapeutic developer customer base.

TypeDirect peer
Description

Eurofins Genomics provides commercial DNA synthesis, gene synthesis, and sequencing services to pharmaceutical, biotech, and academic customers. It competes directly with Applied DNA's PCR-based LinearDNA product in the custom synthetic DNA market.

TypeDirect peer
Description

Twist Bioscience offers silicon-based DNA synthesis and is a direct competitor in synthetic DNA manufacturing for mRNA, gene therapy, and synthetic biology applications. Like Applied DNA, Twist serves pharma, biotech, and academic customers with high-fidelity synthetic DNA, but at significantly greater scale.

TypeRegional player
Description

AlpVision provides digital and covert marking-based anti-counterfeiting and authentication solutions for pharmaceuticals and consumer goods, directly overlapping Applied DNA's CertainT/SigNature DNA authentication offering for supply chain security.

TypeBroad incumbent
Description

Thermo Fisher is a broad life sciences incumbent whose bioscience tools and bioproduction businesses (including Patheon CDMO services) overlap heavily with Applied DNA's DNA/mRNA manufacturing and authentication offerings. It dwarfs Applied DNA in scale and acts as a large competitor in supply chain authentication and molecular biology tools.

TypeDirect peer
Description

IDT is one of the largest commercial manufacturers of custom DNA and RNA oligos and gene synthesis services, with a comparable customer base in pharma, biotech, and academic research. Applied DNA competes with IDT in PCR-based synthetic DNA and oligo production for therapeutics and diagnostics.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Customer concentration

Classification, Details

Named customers7 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment4 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile4 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature4 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles5 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

Subsidiaries2 records

Each record includes

Name, Acquired on, Relationship type, Type, Business focus

Compliance6 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds18 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors6 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A2 records

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Applied DNA Sciences

Therapeutic DNA Manufacturingadnas.com

Applied DNA Sciences (now BNB Plus Corporation, NASDAQ: BNBX) sells PCR-produced LineaDNA and the Linea IVT mRNA manufacturing platform to pharma, biotech, CDMO and IVD customers via its LineaRx subsidiary, while increasingly deploying capital into a BNB cryptocurrency treasury strategy following its 2025 strategic pivot.

What Applied DNA Sciences does

Applied DNA Sciences, now operating as BNB Plus Corporation (NASDAQ: BNBX, formerly APDN), is a Delaware-incorporated biotechnology company that has undergone a radical strategic transformation in 2025. Historically it sold botanical DNA-based anti-counterfeiting and supply chain authentication services (CertainT, SigNature DNA, fiberTyping) targeting textiles, pharmaceuticals and cannabis; today its commercial center of gravity is the LineaRx subsidiary, which produces enzymatically-synthesized linear DNA (LineaDNA) using proprietary large-scale PCR for mRNA production, gene therapy, cell therapy and veterinary vaccine applications. The Linea IVT platform combines LineaDNA IVT templates with a proprietary chemically-modified RNA polymerase (Linea RNAP, acquired from Spindle Biotech in July 2023) to address plasmid DNA bottlenecks and dsRNA contamination in mRNA manufacturing, and is supported by cGMP-certified production capacity in Stony Brook, NY, a Notice-of-Allowance on the Linea RNAP composition patent (protection into 2041), and a 70%+ manufacturing cost reduction achieved through the Alphazyme partnership.

The company generates revenue through B2B direct enterprise sales of LineaDNA products and custom manufacturing services to pharmaceutical companies, biotech firms, CDMOs and IVD manufacturers, supplemented by authentication services under multi-year contracts; pricing is quote-based and not publicly disclosed. Named enterprise customers include ÚHKT (CAR T Phase I trial), a Global IVD Manufacturer, Kudo Biotechnology, a Top-20 pharmaceutical manufacturer, an APAC-based mRNA CDMO and a US CRISPR/mRNA therapeutics developer, with veterinary research conducted alongside Cornell University. In June 2025 the company closed Applied DNA Clinical Labs and executed a 27% workforce reduction to focus resources on LineaRx; subsequently it rebranded as BNB Plus Corporation, changed its NASDAQ ticker to BNBX and committed up to $58M in private placement proceeds to a BNB cryptocurrency digital asset treasury strategy, pivoting its capital deployment away from pure biotech operations while retaining the LineaRx business as a continuing operating segment.

Applied DNA Sciences firmographics

Firmographics
Name
Applied DNA Sciences
Legal name
Applied DNA Sciences, Inc.
Website
https://adnas.com
Company type
Public
Founded year
1987
Operating status
Operating
Headcount range
11–50 employees
Short description
Applied DNA Sciences (now BNB Plus Corporation, NASDAQ: BNBX) sells PCR-produced LineaDNA and the Linea IVT mRNA manufacturing platform to pharma, biotech, CDMO and IVD customers via its LineaRx subsidiary, while increasingly deploying capital into a BNB cryptocurrency treasury strategy following its 2025 strategic pivot.
Ownership category
akta.pro rank

Where Applied DNA Sciences is headquartered

Location

Headquarters

HQ city
Stony Brook
HQ country
United States
HQ region
North America

Offices3 records

Markets served

Applied DNA Sciences business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Operations, Personnel, Supply Chain, Marketing or Sales

Revenue model

  1. Therapeutic DNA Production (LineaRx): Sale of LineaDNA products for use in mRNA production, gene therapy, cell therapy, and veterinary medicine applications. Revenue from IVT templates and related products for biotherapeutic manufacturing.
  2. Molecular Diagnostics Testing Services (Applied DNA Clinical Labs): PCR-based DNA and RNA detection services for molecular diagnostics and genetic testing, including COVID-19 surveillance and pharmacogenomic testing
  3. Supply Chain Security and Authentication: DNA-based authentication services (CertainT, SigNature, fiberTyping) for industrial supply chain security including textiles, pharmaceuticals, and cannabis

Pricing tiers

ModelBillingPrice
OtherMulti-year contractEnterprise/B2B pricing

Go-to-market motion1 record

Distribution channels3 records

Marketing channels6 records

Applied DNA Sciences product offering

Product offering

Core offering

Applied DNA Sciences, through its LineaRx subsidiary, manufactures enzymatically-produced linear DNA (LineaDNA) via proprietary large-scale PCR for use in mRNA production, gene therapy, and cell therapy applications. The company also offers DNA-based supply chain authentication services (CertainT, SigNature DNA, fiberTyping) for textiles, pharmaceuticals, and cannabis, and operates a cGMP manufacturing facility for therapeutic DNA production.

Product overview

Applied DNA Sciences operates primarily through its LineaRx subsidiary, offering a portfolio centered on enzymatic DNA production. The core offering is the LinearDNA platform—a cell-free PCR-based DNA manufacturing system that produces high-fidelity DNA constructs (100bp to 20kb) as an alternative to plasmid-based production. This platform feeds into the Linea IVT platform, which combines LinearDNA with proprietary Linea RNAP for mRNA and saRNA manufacturing. The company previously operated Applied DNA Clinical Labs (now ceased) for molecular diagnostics, and maintains CertainT/SigNature DNA authentication services for supply chain security. Recent strategic shift includes pivot to BNB cryptocurrency treasury management.

Differentiator

Problem solved

Functional benefit

Brands

  • LineaDNA: Enzymatically-produced linear DNA platform for nucleic acid-based therapeutics including mRNA production, gene therapy, and cell therapy applications
  • LineaIVT
  • LineaRx
  • CertainT

Products and services

  • LineaRx Majority-owned subsidiary focused on enzymatic production of LinearDNA for use in mRNA production, gene therapy, cell therapy, and advanced therapeutic modalities.
  • LineaDNA (LinearDNA) Enzymatically-produced linear DNA manufactured via proprietary large-scale PCR-based platform. Produces high-fidelity DNA constructs ranging from 100bp to 20kb in quantities from milligrams to grams, free of adventitious DNA sequences. Alternative to plasmid-based DNA manufacturing.
  • Linea IVT Platform Combines enzymatically-produced LineaDNA IVT templates with proprietary Linea RNA polymerase (RNAP) to enable mRNA and saRNA manufacturers to produce high-quality mRNA faster, eliminating plasmid DNA as starting material and reducing dsRNA contamination.
  • Linea RNAP Proprietary chemically-modified RNA polymerase enzyme acquired from Spindle Biotech. Core component of the Linea IVT platform enabling mRNA manufacturers to produce better mRNA faster with reduced dsRNA contamination. US patent protection expected into 2041.
  • cGMP LinearDNA Production GMP-compliant manufacturing capabilities for therapeutic DNA production. Facility integrates rapid enzymatic PCR-based DNA production within cGMP framework ensuring thorough documentation and QC analysis, supporting transition from discovery to clinical and commercial applications.
  • CertainT Authentication DNA-based authentication platform for supply chain security enabling verification of product authenticity through genetic polymorphism, molecular taggants, isotopic signatures, or other identifiers. Covers textile authentication, supply chain security, and anti-counterfeiting applications.
  • SigNature DNA Proprietary DNA genotyping and mass-spectrometry based authentication service for identifying and verifying materials throughout supply chains. Uses molecular taggants for product authentication and supply chain integrity verification.
  • fiberTyping DNA-based fiber authentication service for textile supply chain verification, enabling identification of fiber composition and origin to prevent counterfeiting and ensure quality control.
  • LinearDNA-LNP Vaccine Platform Lipid nanoparticle delivery system for LinearDNA constructs enabling intramuscular administration without electroporation. Enables therapeutic applications including cancer vaccines, protein replacement, and cell/gene therapies with simplified delivery compared to traditional approaches.
  • TR8 PGx Pharmacogenomic sub-panel for indication-specific use, complementing full-panel testing. First sub-panel launched for Pre-emptive Oncology Care relating to fluoropyrimidine-based cancer therapeutics.

Quantifiable outcome

  • Over 70% reduction in Linea RNAP manufacturing costs
  • +2 more outcomes

Companies that use Applied DNA Sciences

Customer profile

Named customers7 records

Segments4 records

Ideal customer profiles4 records

Applied DNA Sciences technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature4 records

Applied DNA Sciences partnerships and signals

Strategic signal

Partnerships

Six partnerships are on record, tiered core and secondary.

  • ÚHKT (Institute of Hematology and Blood Transfusion)coreStrategic or Co-development Partner · 18 December 2024ÚHKT utilizing Linea DNA as critical component in CD123-specific CAR T-cell therapy manufacturing. Linea DNA enables non-viral workflow to reduce manufacturing costs and timelines. Phase I clinical trial approved by Czech regulatory authority.
  • HDT BiosecondaryStrategic or Co-development Partner · 25 April 2024Awarded contract for rapid vaccine development program
  • Alphazyme LLC (Maravai LifeSciences)coreTechnology or Integration · 18 March 2024Manufacturing scale-up agreement for Linea RNAP. Alphazyme performed manufacturing process development to scale Linea RNAP from research to commercial scale. Project resulted in over 70% reduction in manufacturing costs and quantity sufficient for near-term demand.
  • Kudo BiotechnologycoreStrategic or Co-development Partner · 14 December 2023Joint development agreement to integrate Linea IVT platform into Kudo Bio's commercial mRNA manufacturing workflows. Companies seeking to optimize mRNA quality, yields, and dsRNA mitigation at manufacturing scale. Plans for global co-marketing relationship.
  • Cornell University College of Veterinary MedicinesecondaryStrategic or Co-development Partner · 14 September 2023Sponsored research agreement for translational research to accelerate development of LineaDNA-LNP veterinary vaccine platform. Evaluating multiple LNP formulations and DNA sequence optimization for maximum immunogenicity.
  • Spindle BiotechcoreTechnology or Integration · 13 July 2023Acquisition of Spindle Biotech for RNA manufacturing technology. Acquired Linea RNAP technology and expertise to expand mRNA production capabilities and address dsRNA contamination issues.

Scale indicators8 records

Recent moves8 records

Expansion highlights6 records

Applied DNA Sciences competitors and assessment

Company assessment

Direct peers

  • GenScript: GenScript provides gene synthesis, plasmid manufacturing, and protein services to therapeutic developers, overlapping Applied DNA's enzymatic DNA production for mRNA and gene therapy customers. Both target pharma/biotech CDMO and academic customers with custom DNA and RNA products.
  • Aldevron (Danaher): Aldevron is a CDMO producing plasmid DNA, mRNA, and proteins for cell and gene therapy developers. It competes head-on with Applied DNA's LineaRx offering as a supplier of DNA inputs to gene therapy and cell therapy manufacturers.
  • TriLink BioTechnologies (Maravai LifeSciences): TriLink is a leading mRNA and nucleic acid CDMO that manufactures IVT templates, mRNA, and CleanCap capping analog — directly overlapping Applied DNA's LineaDNA IVT and Linea IVT platform offering for mRNA therapeutics developers. Both target the same CDMO and therapeutic developer customer base.
  • Eurofins Genomics: Eurofins Genomics provides commercial DNA synthesis, gene synthesis, and sequencing services to pharmaceutical, biotech, and academic customers. It competes directly with Applied DNA's PCR-based LinearDNA product in the custom synthetic DNA market.
  • Twist Bioscience: Twist Bioscience offers silicon-based DNA synthesis and is a direct competitor in synthetic DNA manufacturing for mRNA, gene therapy, and synthetic biology applications. Like Applied DNA, Twist serves pharma, biotech, and academic customers with high-fidelity synthetic DNA, but at significantly greater scale.
  • Integrated DNA Technologies (IDT, Danaher): IDT is one of the largest commercial manufacturers of custom DNA and RNA oligos and gene synthesis services, with a comparable customer base in pharma, biotech, and academic research. Applied DNA competes with IDT in PCR-based synthetic DNA and oligo production for therapeutics and diagnostics.

Broad incumbents

  • BioNTech: BioNTech is an mRNA therapeutics developer and manufacturer that both consumes IVT DNA inputs (overlapping with Applied DNA's customer base) and is developing proprietary manufacturing capabilities that could substitute for external CDMOs like LineaRx.
  • Thermo Fisher Scientific: Thermo Fisher is a broad life sciences incumbent whose bioscience tools and bioproduction businesses (including Patheon CDMO services) overlap heavily with Applied DNA's DNA/mRNA manufacturing and authentication offerings. It dwarfs Applied DNA in scale and acts as a large competitor in supply chain authentication and molecular biology tools.

Emerging players

  • Codexis: Codexis engineers enzymes and biocatalysts for nucleic acid and small molecule manufacturing, including DNA/RNA synthesis applications. Its enzyme engineering capability is adjacent to Applied DNA's Linea RNAP and PCR-based enzymatic DNA approach and could become a competitor or partner in enzyme-based nucleic acid manufacturing.

Regional players

  • AlpVision: AlpVision provides digital and covert marking-based anti-counterfeiting and authentication solutions for pharmaceuticals and consumer goods, directly overlapping Applied DNA's CertainT/SigNature DNA authentication offering for supply chain security.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Customer concentration

Applied DNA Sciences social profiles

Digital presence

Applied DNA Sciences compliance and trust

Trust signal

Compliance6 records

Applied DNA Sciences financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Applied DNA Sciences leadership team

Management profile

Number of profiles

Profiles5 records

Applied DNA Sciences subsidiaries and ownership

Company hierarchy

Subsidiaries2 records

Applied DNA Sciences funding detail

Funding detail

Funding overview

Funding rounds18 records

Investors6 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Applied DNA Sciences M&A and investment

M&A and investment

M&A2 records

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Applied DNA Sciences

What does Applied DNA Sciences do?

Applied DNA Sciences, through its LineaRx subsidiary, manufactures enzymatically-produced linear DNA (LineaDNA) via proprietary large-scale PCR for use in mRNA production, gene therapy, and cell therapy applications. The company also offers DNA-based supply chain authentication services (CertainT, SigNature DNA, fiberTyping) for textiles, pharmaceuticals, and cannabis, and operates a cGMP manufacturing facility for therapeutic DNA production.

Is Applied DNA Sciences a public or private company?

Applied DNA Sciences is a public company. It is classified as public and is currently operating.

When was Applied DNA Sciences founded?

Applied DNA Sciences was founded in 1987. It employs 11 to 50 people.

Where is Applied DNA Sciences based?

Applied DNA Sciences is headquartered in Stony Brook, United States, in the North America region.

How does Applied DNA Sciences make money?

Three revenue lines are on record. Therapeutic DNA Production (LineaRx) is the primary driver. The others are molecular Diagnostics Testing Services (Applied DNA Clinical Labs) and supply Chain Security and Authentication.

Who are Applied DNA Sciences's main competitors?

Direct peers on record are GenScript, Aldevron (Danaher), TriLink BioTechnologies (Maravai LifeSciences), Eurofins Genomics, Twist Bioscience and Integrated DNA Technologies (IDT, Danaher). Broad incumbents are BioNTech and Thermo Fisher Scientific. Codexis is listed as an emerging player. AlpVision is listed as a regional player.

Does Applied DNA Sciences have an API?

No public API is recorded for Applied DNA Sciences.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
Quiver Quantitative$DNA stock is down 9% today. Here's what we see in our data. | DNA Stock NewsDNA stock fell 9% today, with $18.3 million in trading volume. Insiders sold 11 times in six months, and 76 institutional investors added shares while 85 reduced positions. Government contract awards totaled $28.8 million over the past year.American Banking and Market NewsApplied Dna Sciences (NASDAQ:BNBX) vs. Prime Medicine (NASDAQ:PRME) Head to Head ComparisonPrime Medicine and Applied Dna Sciences are compared on financial and analyst metrics. Prime Medicine beats Applied Dna Sciences on 12 of 15 factors, with a consensus price target of $7.47 implying 91.6% upside. Analysts favor Prime Medicine due to stronger ratings and institutional ownership.American Banking and Market NewsApplied Dna Sciences (BNBX) & Its Rivals Critical AnalysisApplied DNA Sciences is compared to its biotechnology rivals on earnings, profitability, valuation, and analyst ratings. Competitors beat it on 11 of 13 factors, including higher revenue and earnings, while Applied DNA Sciences has a sell rating and a higher price-to-earnings ratio.Markets DailyApplied Dna Sciences (BNBX) versus Its Peers Critical ContrastApplied DNA Sciences is compared to its biotechnology peers on 13 factors, including dividends, institutional ownership, profitability, analyst ratings, risk, valuation, and earnings. Peers beat Applied DNA Sciences on 11 of the 13 factors, with higher revenue, earnings, and a lower price-to-earnings ratio. Analysts rate Applied DNA Sciences 1.00 versus 2.54 for peers.American Banking and Market NewsFinancial Contrast: Applied Dna Sciences (BNBX) and Its CompetitorsApplied DNA Sciences is compared to biotechnology peers on institutional ownership, valuation, profitability, risk, dividends, analyst ratings, and earnings. Peers beat Applied DNA Sciences on 11 of 13 factors, including higher revenue, earnings, and a lower price-to-earnings ratio. Analysts rate Applied DNA Sciences less favorably than peers.American Banking and Market NewsHead-To-Head Contrast: Applied Dna Sciences (BNBX) versus Its PeersApplied Dna Sciences is compared to its biotechnology peers on profitability, valuation, and analyst ratings. The company loses on 11 of 13 factors, including lower revenue, higher P/E, and a worse analyst consensus. Its stock is less volatile than rivals, but analysts see less favorable growth.Ticker ReportContrasting Applied Dna Sciences (BNBX) and Its PeersApplied DNA Sciences is compared to biotechnology peers on earnings, valuation, and analyst ratings. Competitors beat it on 11 of 13 factors, including higher revenue and earnings, while Applied DNA Sciences trades at a higher price-to-earnings ratio. Analysts give it a 1.00 rating score versus 2.54 for peers.American Banking and Market NewsApplied Dna Sciences (BNBX) and The Competition Critical ContrastApplied DNA Sciences is compared to biotechnology rivals on profitability, valuation, and ownership. Rivals beat it on 11 of 13 factors, including higher revenue and earnings, while Applied DNA Sciences trades at a higher price-to-earnings ratio. Analysts rate it less favorably than the industry average.American Banking and Market NewsMyriad Genetics (NASDAQ:MYGN) vs. Applied Dna Sciences (NASDAQ:BNBX) Head-To-Head ComparisonMyriad Genetics and Applied DNA Sciences are compared on profitability, analyst ratings, and ownership. Myriad beats Applied on 10 of 13 factors, with a consensus target price of $3.12 and a beta of 1.68. Applied has lower revenue but higher earnings, and Myriad is trading at a lower price-to-earnings ratio.Markets DailyContrasting Applied Dna Sciences (BNBX) & Its PeersApplied DNA Sciences is compared to biotechnology peers on profitability, valuation, and analyst ratings. Peers beat the company on 11 of 13 factors, including higher revenue and earnings, while Applied DNA Sciences has a lower rating score and higher price-to-earnings ratio.